CD74-downregulation of placental macrophage-trophoblastic interactions in preeclampsia by Przybyl, L. et al.
 
Repository of the Max Delbrück Center for Molecular Medicine (MDC) 
in the Helmholtz Association  
 
http://edoc.mdc-berlin.de/15738 
 
 
 
 
 
CD74-downregulation of placental macrophage-trophoblastic 
interactions in preeclampsia 
 
Przybyl, L., Haase, N., Golic, M., Rugor, J., Solano, M.E., Arck, P.C., Gauster, M., Huppertz, B., 
Emontzpohl, C., Stoppe, C., Bernhagen, J., Leng, L., Bucala, R., Schulz, H., Heuser, A., Weedon-
Fekjaer, S., Johnsen, G.M., Peetz, D., Luft, F.C., Staff, A.C., Mueller, D.N., Dechend, R., Herse, F. 
 
 
 
 
 
This is the final version of the accepted manuscript. The original article has been published in final 
edited form in: 
 
Circulation Research 
2016 JUN 24 ; 119(1): 55-68 
2016 MAY 19 (originally published online) 
doi: 10.1161/CIRCRESAHA.116.308304 
 
Publisher: American Heart Association 
© 2016 American Heart Association, Inc. 
CD74-downregulation of placental macrophage-trophoblastic interactions in 
preeclampsia 
Running head: Przybyl, CD74 and preeclampsia  
Lukasz Przybyl1,2, MS; Nadine Haase1,2,3, PhD; Michaela Golic1,2,4, MD; Julianna Rugor1,2, 
MS; Maria Emilia Solano5, PhD; Petra Clara Arck5, MD; Martin Gauster6, PhD; Berthold 
Huppertz6, PhD; Christoph Emontzpohl7; Christian Stoppe7,8, MD; Jürgen Bernhagen7, PhD; 
Lin Leng9, PhD; Richard Bucala9, MD, PhD; Herbert Schulz3,10, PhD; Arnd Heuser3, MD; M. 
Susanne Weedon-Fekjær11,12, PhD; Guro M. Johnsen11,12, PhD; Dirk Peetz13, MD, Friedrich 
C Luft1,3, MD; Anne Cathrine Staff11,12, MD, PhD; Dominik N Müller1,2,3, PhD; Ralf 
Dechend1,2,13 MD, Florian Herse1,2,3, PhD 
 
1Experimental and Clinical Research Center, a joint cooperation between the Max-Delbrück 
Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, 
Berlin, Germany 
2Berlin Institute of Health (BIH), Berlin, Germany 
3Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany 
4Charité Universitätsmedizin Berlin, Departments of Obstetrics, Gynecology, and Senology, 
Charité Campus Mitte, Berlin, Germany  
5Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal 
Medicine, University Medical Center Hamburg-Eppendorf, Germany 
6Institute of Cell Biology, Histology and Embryology, Medical University of Graz, Austria 
7Institute of Biochemistry and Molecular Cell Biology, RWTH Aachen University, Germany 
8Department of Anesthesiology, RWTH Aachen University, Germany 
9Department of Internal Medicine, Yale University School of Medicine, New Haven, 
Connecticut, USA 
10Cologne Center for Genomics (CCG), University of Cologne, Germany 
11Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway 
12University of Oslo, Norway  
13HELIOS-Klinikum, Berlin, Germany 
 
Corresponding Author: 
Florian Herse, PhD 
Experimental and Clinical Research Center 
Lindenberger Weg 80, 13125 Berlin, Germany  
Tel: +49-450-540-434 Fax: +49 30-450-540-944 
E-mail: florian.herse@charite.de 
 
Word count: 8369 Subject code: Pregnancy, Preeclampsia  
2 
 
ABSTRACT 
RATIONALE  
We hypothesized that Cluster of differentiation 74 (CD74) downregulation of placental 
macrophages, leading to altered macrophage-trophoblast interaction, is involved in 
preeclampsia. 
OBJECTIVE 
Preeclamptic pregnancies feature hypertension, proteinuria and placental anomalies. 
Feto-placental macrophages regulate villous trophoblast differentiation during placental 
development. Disturbance of this well-balanced regulation can lead to pathological 
pregnancies.  
METHODS AND RESULTS 
We performed whole genome expression analysis of placental tissue. CD74 was one 
of the most downregulated genes in placentas from preeclamptic women. By RT-PCR, we 
confirmed this finding in early onset (<34 gestational week, n=26) and late onset (≥34 
gestational week, n=24) samples from preeclamptic women, compared to healthy pregnant 
controls (n=28). CD74 protein levels were analyzed by Western blot and flow cytometry. We 
identified placental macrophages to express CD74 by immunofluorescence, flow cytometry 
and RT-PCR. CD74-positive macrophages were significantly reduced in preeclamptic 
placentas compared to controls. CD74-silenced macrophages showed that the adhesion 
molecules ALCAM, ICAM4, and Syndecan-2, as well as macrophage adhesion to 
trophoblasts were diminished. Naïve and activated macrophages lacking CD74 showed a 
shift towards a pro-inflammatory signature with an increased secretion of TNFα, CCL5, and 
MCP-1, when co-cultured with trophoblasts compared to control macrophages. Trophoblasts 
stimulated by these factors express more CYP2J2, sFlt1, TNFα and IL-8. CD74-knockout 
mice showed disturbed placental morphology, reduced junctional zone, smaller placentas 
and impaired spiral artery remodeling with fetal growth restriction. 
CONCLUSIONS 
CD74 downregulation in placental macrophages is present in preeclampsia. CD74 
downregulation leads to altered macrophage activation towards a pro-inflammatory signature 
and a disturbed crosstalk with trophoblasts.  
 
KEY WORDS: CD74, preeclampsia, macrophages, trophoblasts, immunology 
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INTRODUCTION 
 Preeclampsia (PE) is a pregnancy-related disorder characterized by new-onset 
hypertension (>140/90 mm Hg) after the 20th week of pregnancy and proteinuria (>300 mg/l 
per 24-hour) or in association with thrombocytopenia, impaired liver function, development of 
renal insufficiency, pulmonary edema, or new-onset cerebral or visual disturbances.1 Overall, 
5-10% of all pregnancies worldwide develop PE, the leading cause of morbidity and mortality 
in mother and child.2  
Immune cell and trophoblastic-cell interactions facilitate placental growth by a well-
balanced regulation, including interactions between maternal immune cells and extravillous 
trophoblast as well as between feto-placental immune cells and villous trophoblast. 
Pregnancy initiates a profound adaptation of the maternal immune system to the 
semiallogeneic fetus, and a significant inflammatory response has been described in 
preeclamptic women.3, 4 Chemokines such as monocyte chemotactic protein-1 (MCP-1) and 
chemokine (C-C motif) ligand 5 (CCL5) are elevated in PE and enhance maternal 
monocytes/macrophage recruitment.5-7 Maternal macrophages have been shown to 
participate in intrauterine growth restriction (IUGR) and PE, perhaps related to cytokine 
release.8 In the decidua, activated maternal macrophages produce high levels of tumor 
necrosis factor α (TNFα). Extravillous trophoblasts express the receptors of TNFα, and 
interactions between TNFα and its receptor are described to induce trophoblast apoptosis in 
vitro.9, 10 Moreover, invasion, migration, and proliferation of extravillous trophoblasts appear 
to be regulated by local cytokine concentrations.11-14 
Hofbauer cells are placental macrophages of fetal origin and play a direct role in early 
placental development. They differentiate from progenitor cells within the population of 
mesenchymal cells in the villous stroma or from penetration of embryonic/fetal bone marrow-
derived monocytes into the villous stroma.15 Hofbauer cells are associated with several 
pregnancy complications such as chorioamnionitis, spontaneous abortion, and fetal 
metabolic storage disease.16 Hofbauer cells contribute to the placental expression of anti-
angiogenic factors and their dysregulation in preeclamptic placenta.17  
The HLA class II histocompatibility antigen gamma chain, also known as cluster of 
differentiation 74 (CD74) when expressed on cell surfaces, is the MHC II invariant chain (Ii) 
protein that is involved in antigen presentation and crucial for biogenesis.18 CD74 is also a 
high-affinity binding protein for the pleiotropic inflammatory cytokine macrophage migration 
inhibitory factor (MIF). Following its activation on the cell membrane, CD74 transduces 
signaling and triggers various downstream responses including inflammatory protein 
expression and modulation of cell survival.19 MIF also acts as a major regulator of 
inflammatory cell recruitment and atherogenesis by activating CXCR2/4.20 In the first-
trimester placenta, trophoblasts express and release MIF that modulates monocyte activity.21-
23 Furthermore, CD74 has been described in a soluble form (sCD74) that neutralizes MIF 
signal transduction in patients with autoimmune liver disease.24 Soluble CD74 plasma levels 
correlate with the concentration of a complex that is formed between sCD74 and soluble 
HLA-DR (sCD74/sHLA-DR).25 Interestingly, sHLA-DR levels are significantly lower in the 
circulation of preeclamptic women when compared to women with normally progressing 
pregnancies.26 Based on microarray gene expression data from clinical specimens, we tested 
the hypothesis that preeclampsia is associated with a CD74-induced disturbed placentation. 
We used in vitro models and a knockout mouse model in vivo to study the pathophysiological 
significance of CD74. 
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METHODS 
Patients 
Human placenta, decidua and blood sampling was approved by the Regional 
Committee of Medical Research Ethics in Eastern Norway and the Medical Faculty of Charité 
Berlin. Placental biopsies and decidual tissue were obtained from 50 preeclamptic women 
and 28 women with normotensive and uncomplicated pregnancies. The PE group was 
divided into early onset PE (<34 gestational week, n=26) and late onset PE (≥34 gestational 
week, n=24). Patient characteristics are shown in Supplemental Table S1. 
Animals 
 Local authorities (LaGeSo, Berlin, Germany) approved all experiments. Primary 
cultures of macrophages were generated from the bone marrow of male 10-12 week old wild-
type (C57Bl/6JOlaHsd) mice; Harlan Laboratories, Rossdorf, Germany) or CD74 knockout 
(B6-(Cd74)tm) mice. To evaluate the preeclamptic phenotype, wild-type (C57Bl/6JOlaHsd) 
and CD74 knockout (B6-(Cd74)tm) mice were bred. Doppler studies were performed on day 
15/17 on anesthetized (1.5% isoflurane) mice. The hair was removed from the abdomen, and 
pre-warmed gel was used as an ultrasound-coupling medium. The pregnant mice were 
imaged with an ultrasound biomicroscope and a 30-MHz or 40-MHz transducer at 30 frames 
per second (Model Vevo 660, VisualSonics Inc). Peak systolic velocity (PSV) and end-
diastolic velocity (EDV) were measured and the resistance index (RI=(PSV−EDV)/PSV) was 
calculated. 
Isolation of primary cells from human placenta 
 All placentas were removed from fetal membranes, basal plate, umbilical cord and 
fibrotic tissue. Villous tissue was minced and washed several times. Various trypsin (Sigma) 
and DNase I (Roche) digestion steps were used and supernatants were filtered and collected 
in New Born Calf Serum (Biochrome). For Hofbauer cell isolation supernatant was discarded 
and undigested tissue was digested further with collagenase A (Roche), DNase I and cell 
suspensions were loaded on Percoll (GE Healthcare) gradual gradients. For primary 
trophoblasts, cells were negatively immunopurified using HLA-ABC (DakoCytomation) and 
magnetic dynabeads (Dynal Biotech). 
Macrophage preparation and cell culture 
 Macrophages were generated from two different origins: Human peripheral blood 
mononuclear cells (PBMCs) and mouse bone marrow-derived (BMD). PBMCs derived 
macrophages: 80 ml of blood were drawn from human healthy donors. The study was 
approved by the Regional Committee of Medical Research Ethics (Charité). PBMCs were 
purified by Ficoll gradient centrifugation and an adhesion step.  
BMD macrophages: Cells were isolated from the femur and tibia of freshly euthanized 
mice. For macrophage differentiation, 10 x 106 bone-marrow derived cells were cultivated in 
50 ml of differentiation media for 7 d in sealed, hydrophobic Teflon® bags (FT FEP 100 C 
(DuPont), American Durafilm).  
SGHPL-4 cells derived from primary human first trimester extravillous trophoblasts 
(transfected with the early region of SV40) were a kind gift from Judith E. Cartwright (St 
George’s University of London, London, United Kingdom).  
Microarray analysis 
 Microarray analysis of M(-) and M(IL-4) was done with the Illumina HumanHT-
12_V3_0_R2 according the Minimum Information About a Microarray Experiment (MIAME) 
criteria. Data is provided at ArrayExpress under accession number E-MTAB-3309. 
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Expanded methods are described in the online supplement. 
 
RESULTS 
Downregulation of placental and circulating CD74 in PE 
 Microarray analysis performed on placental tissue showed downregulation of CD74 
expression by 3 different nucleotide sequences (ILMN_1761464, ILMN_2379644, 
ILMN_1736567).27 This observation was confirmed in a different cohort of patients, dividing 
the preeclamptic group into early onset (<34 gestational week) and late onset (≥34 
gestational week) of preeclampsia (Supplemental Table S1) by real-time RT-PCR. We found 
that CD74 was significantly downregulated in early onset PE by a factor of 2.3 (p<0.001) and 
late onset PE by a factor of 1.9 (p<0.01) (Figure 1A). Western blot analysis of 4 controls vs. 4 
preeclamptic placentas confirmed this finding. CD74 protein level was clearly diminished in 
both early- and late onset preeclamptic placentas (Figure 1B). Moreover, flow cytometry 
analysis on the whole placental cell population of 6 healthy and 10 late onset preeclamptic 
placentas showed a significantly lower presentation of CD74 in cells of late onset 
preeclamptic placentas (Figure 1C). Decidua showed no differential CD74 expression 
between groups (Supplemental Figure S1A). In the PE group, placental CD74 expression 
negatively correlated to the serum ratio of the soluble Fms-like tyrosine kinase 1 (sFlt1) and 
the placental growth factor (PLGF), the sFlt1/PLGF ratio, but not in controls (Supplemental 
Figure S1D). CD74 not only serves as invariant chain for MHC class II proteins and as a MIF 
receptor on the cell surface, but also circulates as a soluble ectodomain, termed sCD74.24 
We thus also analyzed serum sCD74 levels in our cohort and detected somewhat lower 
mean levels in both preeclamptic groups compared to controls, although these results were 
not statistically significant (Supplemental Figure S1B). Circulating levels of the binding 
partner of sCD74, macrophage migration inhibitory factor (MIF), were correspondingly 
enhanced during preeclamptic disease, but without reaching statistical significance 
(Supplemental Figure S1C). 
Localization of CD74 in placental macrophages (Hofbauer cells) 
 Following differential expression of CD74 in preeclamptic placentas, we identified the 
specific cell type that expresses CD74. Given the low amounts of lymphocytes in placenta, 
we focused on CD74 levels in two main placental populations – trophoblasts (CK7+) and 
macrophages (CD14+). It appeared that in healthy control placentas only 2.6±0.8% of 
trophoblasts were positive for CD74 (CK7+CD74+), in contrast to 93.1±1.1% of macrophages 
(CD14+CD74+) (Figure 2A). Furthermore, immunofluorescence co-staining was performed on 
placental villous tissue for trophoblasts (CK7) and Hofbauer cells (CD163) with CD74. We 
could confirm that trophoblasts were negative for CD74 (CK7+CD74-) while Hofbauer cells 
were positive (CD163+CD74+) (Figure 2B). 
To investigate CD74 mRNA expression levels we isolated primary trophoblasts and 
primary Hofbauer cells from healthy human term placentas and compared them with 
placental tissue, early trophoblast cell line (SGHPL-4) and blood-derived macrophages 
(human M(IL4)). We confirmed that isolated Hofbauer cells showed high levels of CD74 
expression, similar to human M(IL4) and M(-), while primary trophoblasts and SGHPL-4 cells 
showed low levels (Supplemental Figure S2). Accordingly, in Hofbauer cells and blood 
derived macrophages, but not in SGHPL-4 cells the phosphorylation of ERK (p44/42) could 
be activated by stimulation with the CD74 ligand MIF (Supplemental Figure S3). 
To combine both findings, the observed placental downregulation of CD74 in 
preeclamptic placentas and the expression of CD74 on placental macrophages, we then 
compared CD74 levels expressed on CD14+ Hofbauer cells from healthy and preeclamptic 
placentas. Significantly fewer placental CD14+ macrophages co-expressed CD74 in late 
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preeclampsia (81.2±4.4%), compared with healthy controls (93.1±1.1%) (p<0.05) (Figure 2C, 
left panel). Additionally, CD74+ cells of preeclamptic placentas showed lower intensity of 
CD74 staining as compared to controls, shown by mean fluorescence intensity of CD74 
(16283±1244 vs 7693±1392 a.u., p<0.01) (Figure 2C, middle panel). The frequency of CD14+ 
macrophages did not differ between control and preeclamptic placentas (Figure 2C, right 
panel).  
Impaired function of macrophages lacking CD74 
 Since Hofbauer cells are considered to be M2 (also named alternatively activated) 
macrophages28, we aimed to establish an in vitro preeclamptic-model of CD74 
downregulated Hofbauer cells by transfecting M(IL-4) with small interfering RNA (siRNA) 
against CD74 (siCD74) and an appropriate non-targeting control (NT). However, the current 
characterization of placental macrophages might be not sufficient regarding activation status, 
we therefore used M(-) for silencing protocols additionally. Downregulation of CD74 was 
confirmed by gene expression via real-time RT-PCR (Supplemental Figure S4A) and at the 
protein level by Western blot (Supplemental Figure S4B) (data shown for M(IL-4)). mRNA 
was processed and differential expression (NT vs. siCD74) (n=6 each) was revealed by 
whole transcriptome analysis. Subdued parametric three way ANOVA resulting p-values 
were Benjamini Hochberg FDR corrected, furthermore, probes undergoing 5% FDR in 
“silencing” were average linkage-clustered using standardized signal values and the 
Euclidean distance function. 30 probes, representing 27 known genes, were significantly 
differentially expressed by CD74 silencing (5% FDR), 25 of them were downregulated in 
CD74-silenced samples and 2 were up-regulated and represented on the heat map (Figure 
4A, left panel). These 27 genes were matched to the literature in respect to placenta. We 
found that Ras homologue gene family, member A (RHOA), mitogen-associated protein 
kinase 3 (MAPK3) and polycystic kidney disease gene 1 (PKD1) were linked to pregnancy 
and are highlighted in orange. For further analysis, genes that followed FDR <65% were 
plotted and are shown in Figure 4A (right panel). To determine possible interactions of 
differently regulated genes, datasets of these 226 genes with altered expression were 
analyzed using Ingenuity Pathway Analysis Tool (IPA). The top ten list of canonical pathways 
was identified by IPA. The pro-inflammatory IL-1 signaling pathway was the most significantly 
enriched. Among the identified biological functions we found cell morphology, connective 
tissue disorders and immunological diseases (Supplemental Figure S5). Strongly 
downregulated genes within the 226 dysregulated genes were adhesion molecules – 
activated leukocyte cell adhesion molecule (ALCAM), intracellular adhesion molecule 4 
(ICAM4) and syndecan-2 (SDC2) – which are presented in red (Figure 4A, right panel). We 
confirmed ALCAM, ICAM4 and SDC2 downregulation in M(IL-4) lacking CD74 by real-time 
RT-PCR (n=27 each) (Supplemental Figure S6). 
As gene expression of adhesion molecules was downregulated in macrophages 
lacking CD74, adhesion assay with M(IL-4) macrophages and first trimester trophoblast cell 
line SGHPL-4 was performed. There was significantly less M(IL-4) adherence to the SGHPL-
4 layer in the siCD74-treated group when compared to NT, as documented by microscopy 
and measured by fluorescence intensity (Figure 4B). 
To reveal the impact of CD74 deficiency on M2 macrophages, we also generated 
BMD macrophages from CD74 knockout (CD74-/-) mice. BMD M(-) and M(IL-4+IL-13) 
showed high CD74 expression when derived from WT, which was absent in CD74-/- 
macrophages (Supplemental Figure S7). First, we activated CD74-/- and WT macrophages 
with IL-4+IL-13 to promote a M2 phenotype and analyzed the secretion of different cytokines 
(Figure 5A). Surprisingly, M2 macrophages from CD74-/- mice secreted significantly more 
TNFα (1.8-fold) and CCL5 (1.7-fold) compared to WT-derived macrophages indicating a shift 
towards a pro-inflammatory phenotype. Co-culturing M2 CD74-/- macrophages with 
trophoblast cell line SGHPL-4 further increased the secretion of these cytokines TNFα (2.7-
fold) and CCL5 (2.7-fold)). Interestingly, the secretion of chemokine MCP-1 was 4.1-fold only 
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induced in BMD M(IL-4+IL-13) from CD74-/- (compared to WT) when co-cultured with 
SGHPL-4. SGHPL-4 cell count was significantly lowered when co-cultured with BMD M(IL-
4+IL-13) from CD74-/- compared to BMD M(IL-4+IL-13) from WT (4284±225 vs. 5200±252 
cells) (Figure 5B). SGHPL-4 cells stimulated with the combination of MCP-1, CCL5 and 
TNFα for 6h and 24h expressed more Cytochrome P450 Subfamily 2J Polypeptide 2 
(CYP2J2), sFlt1, TNFα and Interleukin 8 (IL-8). The sFlt1/PLGF ratio was also enhanced 
(Figure 5C). 
To reveal the impact of CD74-/- on M1 and M2 macrophage activation, we analyzed 
for M1 activation the pro-inflammatory marker genes Tnfα, Il-6, Ccl5, nitric oxide synthase 2 
(Nos2), Mcp-1 and for M2 activation Resistin-like molecule alpha1 (Fizz1), mannose receptor 
1 (Mrc-1) and programmed death ligand 2 (Pd-l2) in BMD M(-) and M(IL-4+IL-13) from CD74-
/- compared to WT (Figure 6). Arginase 1 (Arg1) is known to be activated after M1 and M2 
stimuli. LPS used to induce M1 activation (M(LPS)). The activation by IL-4+IL-13 and LPS 
led to a typical marker gene signature in BMD macrophages from both origins, CD74-/- and 
WT. Non-activated M(-) macrophages from CD74-/- origin showed an enhanced expression of 
Tnfα (1.6-fold), Il-6 (2.9-fold), Ccl5 (3.7-fold), Nos2 (14-fold)  and Mcp-1 (1.5-fold) compared 
to M(-) WT macrophages, indicating a shift towards a pro-inflammatory signature. Under M2 
conditions, Tnfα and Il-6 were also higher expressed in M(IL-4+IL-13) CD74-/- macrophages. 
LPS activation (M(LPS)) led to a higher expression of Tnfα, Il-6, Nos2 and Mcp-1 in CD74-/- 
macrophages indicating again a shift towards a pro-inflammatory macrophage phenotype. 
Disturbed placental/fetal phenotype of CD74 knockout (CD74-/-) mice 
To test the hypothesis that CD74 is important for pregnancy and fetal development, 
we analyzed the pregnancy and the uteroplacental unit of the CD74-/- mice. CD74 expression 
was absent on protein level in the placenta of CD74-/- and clearly detectable in wild-type (WT) 
mice (Supplemental Figure S8). Fetal weight on day 18 was significantly lower in CD74-/- 
mice (0.71±0.02 g) compared to WT (0.91±0.03 g) (Figure 7A). Placenta weight (0.1 g in 
CD74-/- vs. 0.11 g in WT) and litter size (7 in CD74-/- vs. 9 in WT pups) was also diminished. 
Histomorphological analysis revealed a significant overall reduction of the placental area in 
CD74-/- mice, compared to WT placentas (Figure 7B). Additionally, CD74-/- placentas 
presented significant structural changes, as the ratio between two functional placental zones, 
the labyrinth and the junctional zone, was increased in placentas from CD74-/- placentas 
compared to WT controls (Figure 7B, lower panel). This increase was due to a significant 
reduction of the junctional zone in CD74-/- placentas, whereas the labyrinth area remained 
unaltered between CD74-/- and WT mice (Supplemental Figure S9). The spiral artery 
remodeling was also impaired in arteries of the decidua basalis and mesometrial tissue 
(Figure 8). Areas are indicated in Supplemental Figure S10A. CD74-/- mice showed 
significantly more α-actin, representing an abnormal remodeling process (Figure 8). Arteries 
of CD74-/- mice were smaller, indicated by artery area (µm2) and perimeter (µm) when 
compared to WT mice (Supplemental Figure S10B). Doppler waveform analysis of the distal 
uterine artery showed a significant increase of the resistance index (RI) of the CD74-/- mice 
(0.51±0.02 RI) compared to WT (0.44±0.02 RI) (Supplemental Figure S11).  
A putative maternal syndrome was characterized by blood pressure and albuminuria 
(Supplemental Figure S12). However, on day 15 of pregnancy, mean arterial pressure (MAP) 
and albuminuria were not significantly changed in CD74-/- mice. To analyze the effects of 
whole body knock out (CD74-/-) in the female mice on fetal growth restriction and lowered 
placental weights, we transferred fertilized oocytes from CD74-/- mice to WT foster mothers. 
Fetuses and placentas resulting from this model were also smaller compared to fetuses and 
placentas resulting from WT fertilized oocytes (Supplemental Figure S13).  
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DISCUSSION 
 We present novel data to support the notion that CD74 is significantly downregulated 
in third trimester preeclamptic placentas. We successfully localized the origin of CD74 
expression to placental macrophages (Hofbauer cells) and inversely correlated the placental 
CD74 expression to the serum sFlt1/PLGF ratio that is enhanced in the preeclamptic 
circulation. In maternal blood, the shed soluble CD74 and its ligand MIF were not statistically 
significantly altered in the circulation of preeclamptic women. Importantly, macrophages that 
lack CD74 showed a dysregulated interaction with trophoblasts. The adhesion of such 
macrophages to trophoblasts was diminished, while CD74 deficient macrophages exhibited a 
pro-inflammatory phenotype when co-cultured with trophoblasts. Trophoblasts activated by 
those pro-inflammatory stimulus expressed more vasoactive and anti-angiogenic factors. M1 
and M2 activation under LPS and IL-4+IL-13 led to the induction of the respective signature 
genes. Interestingly, M(IL-4+IL-13) CD74-/- M2 macrophages also expressed pro-
inflammatory genes suggesting a shift towards an altered M2 phenotype. Importantly, CD74-/- 
mice showed altered placenta morphology, evidenced by a smaller junctional zone and an 
impaired spiral artery remodeling. This abnormal placentation was accompanied by fetal 
growth restriction and an increased resistance index of the distal uterine arteries. Our results 
suggest a novel link between preeclampsia and the regulatory interaction of placental 
macrophages and villous trophoblasts with a specific role for CD74.  
The most studied function of CD74 is its chaperone activity, in which CD74 acts as an 
invariant chain for MHC class II proteins and is crucial for antigen presentation.18 Due to the 
importance of antigen presentation in the recognition of fetal cells by the mother, it is 
surprising that little is known about the expression of CD74 in the placenta. Peyman et al. 
showed that trophoblasts do not present MHC class II proteins and CD74 on their cell 
surface. Moreover, those genes seem to be inactive, as the mRNA expression was not 
inducible by interferon-γ, which has been shown to upregulate these proteins in 
macrophages.29 These observations are in line with our findings. We also found that CD74 is 
expressed by placental macrophages and not by trophoblast cells. In human placental 
explants infected by Toxoplasma gondii, a model for induction and suppression of infection, 
CD74 was detected in first but not third trimester trophoblasts, as well as in Hofbauer cells.30 
However, colocalization of CD74 with a marker like CD163 for macrophages or CK7 for 
trophoblast was not performed. The expression of CD74 in general was higher in first 
trimester explants. Interestingly, in this study the production and secretion of the CD74 ligand 
MIF was enhanced in first-trimester placenta after activation of inflammatory processes by 
pathogens. MIF may play an essential role as an autocrine/paracrine mediator in placental 
infection.23, 30 In this context, our finding that expression of CD74 is downregulated in 
preeclampsia suggests a disturbance of the normally balanced immune response to antigens 
in the preeclamptic placenta. MIF expression and concentrations were described in 
pregnancy and preeclampsia by Cardaropoli et al.31 Only in serum of preeclamptic women 
accompanied by fetal growth restriction they found significantly higher MIF levels compared 
to controls. However, that study also failed to show a statistically significant up-regulation in 
the preeclamptic group without fetal growth restriction, which is in line with our findings. 
Inflammatory dysfunction in preeclampsia is mostly described on the maternal side of the 
uteroplacental unit or in maternal circulation. Brewster et al. described that the monocyte 
secretory capacity for different cytokines, including MCP-1 and TNFα, is higher in 
preeclamptic women than in controls.32 MCP-1 secretion can be stimulated by TNFα and IL-
1β in first trimester derived decidual explants.33 The chemokines MCP-1 and CCL5, as well 
as the adhesion molecules ICAM-1 and VCAM-1, are elevated in preeclampsia compared 
with healthy pregnancies, resulting in an overall pro-inflammatory systemic environment.5-7 
Circulating levels of the inflammatory cytokines TNFα, IL-10, INF-γ are controversially 
discussed.34 Our results from the in vitro model also suggest an upregulated expression of 
macrophage signaling molecules such as MCP-1, TNFα and CCL5 as well as a diminished 
adhesion of macrophages to trophoblasts in preeclampsia that may be caused by 
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downregulated CD74. The in-vitro findings show a dysregulation of the well-balanced 
interaction between villous trophoblasts and placental macrophages towards a pro-
inflammatory phenotype. However, this does not illuminate the nature of the differences in 
circulatory in the maternal system. Fest et al. could show that the human THP-1 monocyte 
line expressed and secreted more cytokines and chemokines when co-cultured with 
trophoblasts compared to mono culture. Among these factors were MCP-1 and CCL5. 35 Our 
findings are in line with this observation. We also show an effect of trophoblasts on 
macrophages regarding secretion of TNFα, MCP-1 and CCL5. Furthermore, we showed that 
this effect is enhanced by CD74 downregulation. Further induction of an already existing 
robust inflammatory response during pregnancy by inflammatory cytokines and chemokines 
is already described in preeclampsia.3, 4 Here, we could show that the activation of a 
trophoblast cell line by TNFα, MCP-1 and CCL5 led to an upregulation of the vasoactive 
CYP2J2, the anti-angiogenic factor sFlt1 and the pro-inflammatory TNFa and IL-8. All these 
factors are described to be mechanistically involved in the preeclamptic syndrome.27, 34, 36, 37 
Recently, we described the fact that the CYP2J2 expression is upregulated in preeclamptic 
trophoblasts.27 This uteroplacental upregulation resulted in enhanced CYP2J2 metabolite 
levels in the circulation of preeclamptic women. Furthermore, we tested the vasoactive 
function the metabolite and could show that it induced a chronotropic effect, an endothelial 
dysfunction and a down regulation of the KCa1.1 channel activity. Its function was synergistic 
to angiotensin II. In preeclampsia, angiotensin II sensitivity, endothelial dysfunction and 
alterations in endothelium-dependent vascular contractile properties, are part of the maternal 
syndrome. We now can conclude that the recently described CYP2J2 upregulation in 
preeclamptic trophoblasts could be a mechanism of the here described CD74 depended 
macrophage-trophoblast interaction. We also could show that CD74-/--macrophages show a 
pro-inflammatory shift towards an M(LPS) (or classical macrophage (M1)) phenotype. This 
result is in line with recent findings. Similar shift toward pro-inflammatory M1 phenotype was 
also described in preeclamptic placentas were the increase of M1 macrophages and the 
decrease of M2 macrophages lead to an acute atherosis.38 
Hofbauer cells may play a direct role in early placental development, as early 
placental vasculogenesis is influenced by close contact of Hofbauer cells with endothelial 
progenitor cells in primitive vessels in the first trimester placenta.39 With respect to the 
importance of Hofbauer cells in the early placenta, our study of early third trimester placentas 
show the relevance of CD74 and Hofbauer cells in the middle stage of pregnancy which may 
be of importance in the pathophysiology of preeclampsia and fetal growth restriction. We can 
only speculate that CD74 downregulation is already a feature of immunological dysregulation 
at the beginning of pregnancy or even before conception, the latter being viewed as relevant 
for the development of preeclampsia and/or fetal growth restriction.40 Little is known about 
the transcriptional regulation of CD74. CD74 expression is described to be increased in 
tissue injury disorders and decreased in brain tissue in schizophrenia and bipolar disorder.41, 
42 However, none of these studies could reveal the regulatory mechanisms that underlie the 
regulation of CD74 expression. The regulation of CD74 in different cell types correlates with 
glucose concentrations and an immune activation.41, 43 The inaccessibility of tissue from 
histiotrophic placentas let us just speculate about the mechanisms that lead to the 
downregulation of CD74 in the preeclamptic placental macrophages. Glucose regulates the 
Heme oxygenase-1 that is a central player for immune regulation.44 Furthermore, glucose 
regulates the exosomal signaling by placental cells and the release of cytokines.45 It might be 
that a dysregulation in glucose metabolism at first trimester in pregnancies has adverse 
outcome on the CD74 expression and therefore associates with placental insufficiency. 
Currently, no single nucleotide polymorphism (SNP) is described for the CD74 gene or its 
promoter region. Analysis of SNPs and their association to the genesis of the preeclamptic 
syndrome are growing. Association studies of polymorphisms in inflammatory genes involved 
in preeclampsia are controversial.46 However, further studies to reveal the mechanisms that 
underlie the transcriptional regulation of CD74 are important. 
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The CD74-/- mouse model was established and first described in 1993 by Bikoff et 
al.47 Most publications described the role of CD74 in regulating MHC class II expression and 
function.48 Recently, CD74-/- mice were described to develop spontaneous emphysema in 
association with MIF.49 Mun et al. isolated bone-marrow cells from CD74-/- mice and 
described the mice as indistinguishable from WT littermates in their general health, growth 
rate as well as breeding performance.50 However, this does not reflect our observations. This 
result could be due to different murine backgrounds, as the prior authors crossed 
heterozygous CD74 knockout mice in order to generate homozygous CD74-/- littermates, or 
to an insufficient characterization of fetuses and placentas. Herein, we report that CD74 
deficiency was associated with an altered placentation at late gestation, evidenced by 
smaller placentas and an impaired spiral artery remodeling. Placentas from CD74-/- mice also 
revealed an increased L/Jz ratio, which was mainly due to a decrease of the junctional zone 
area. The junctional zone is composed of spongiotrophoblast, glycogen cells, and a layer of 
giant cells reaching the decidual tissue.51 Although the function of the junctional zone in mice 
is not yet fully understood, it has been shown to support the growth and expansion of the 
labyrinth.51 Moreover, the junctional zone synthesizes and secretes a vast array of cytokines 
and hormones such as placental lactogens, hereby maintaining fetal growth.52-54 Hence, the 
decreased junctional zone observed in CD74-/- mice at late gestation and the impaired spiral 
artery remodeling could account for the increased resistance index of the distal uterine 
arteries and the decreased fetal weight. Moreover, we provide evidence that while the area 
of the labyrinth is unaffected in CD74-/- mice, the relative fraction of the placenta occupied by 
the labyrinth is increased. This relative increase in the size of the labyrinth has been reported 
to naturally occur in small placentas and can be interpreted as an adaptation attempt to meet 
the demands for fetal growth.55 The labyrinth comprises a complex vascular network of 
maternal and fetal blood vessels in close proximity, hereby promoting nutrient and gas 
transfer from mother to fetus. Interestingly, it was shown that the relative increase in the 
labyrinth from small placentas occurs at the expense of the junctional zone, which could 
provide an explanation for the decrease in the area of the junctional zone observed in the 
CD74-/- placentas. We here assessed placental tissue from CD74-/- mice and respective WT 
controls late in gestation and hence, can only speculate that the adaptive changes observed 
in the placentas of CD74-/- mice may have occurred earlier in gestation. A limitation of the 
mouse-model might be the knock-out effect on other cell types than the placental 
macrophages and the whole body knock-out effects in the maternal body. To exclude the 
CD74-/- effect in organs of the female mice, we also provided the CD74-/- two-cell stage 
embryo transfer in WT mice. The observed fetal and placental growths restrictions underline 
the significance of the CD74-/- on the uteroplacental unit. However, in this model, we just can 
speculate that the effects are macrophage driven and not co-stimulated by CD74-/- in other 
placental cell types. Further experiments with a placental macrophage specific knock-out 
model could complete rule out the interaction between macrophages and trophoblasts. The 
maternal syndrome was not developed in CD74-/- mice. One explanation for the lack of 
hypertension in CD74-/- mice could be related to the C57BL/6 genetic background of the 
knockout mice. European C57BL/6 are often resistant to hypertension. Therefore, we cannot 
completely rule out a role of CD74 on blood pressure. Our hypothesis is that the CD74 
downregulation leads to an adverse outcome in placentation resulting in vulnerability for 
preeclampsia and IUGR. We hypothesize that additional triggers could promote a maternal 
syndrome and further studies will be necessary to investigate which second hit is necessary 
in addition to downregulation of CD74 to promote the full clinical picture of preeclampsia. 
Furthermore, our findings are in line with the clinical discussion of preeclampsia and IUGR. 
Both pregnancy complications share risk factors, molecular pathways and the risk for 
developing future cardiovascular.56 Moreover, as preeclampsia is a complex syndrome, the 
lack of CD74 in the mouse model we here used may have been compensated by other 
pathways. Such redundancy of single pathways in the context of maintaining successful 
reproduction has been described in a number of genetically engineered mice.57 
CD74 is significantly downregulated in third trimester preeclamptic placentas. 
Therefore, we propose that CD74 might be involved in the development of preeclampsia. Our 
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data suggests that CD74 is a potential candidate for controlling the well-balanced regulation 
between villous trophoblasts and placental macrophages. Thus, studies on CD74 and the 
macrophage-trophoblast interaction in pregnancy and preeclampsia are essential to enhance 
our knowledge of its modes of action and to evaluate its potential as a therapeutic agent in 
preeclampsia and other placenta dysfunctional complications of pregnancy. 
 
ACKNOWLEDGMENTS  
We thank Juliane Anders, Jutta Meisel, Ilona Kamer, Gabriele N`Diaye, Jana Czychi, 
Dr. Hongqi Lue, May-Britt Köhler, Stefanie Schelenz, Martin Taube, Anika Wehner and 
Thomas Andreas for their excellent technical assistance. We also thank Lise Øhra Levy for 
valuable assistance in patient recruitment and biobank handling and Ralf Kuehn, Rainer 
Kabisch and Sabine Manz from animal facility of MDC/BIH. 
 
SOURCES OF FUNDING 
 The Deutsche Forschungsgemeinschaft (DFG) supported Dr. Herse (HE 6249/1-2, 
HE 6249/4-1), Dr. Dechend (DE 631/9-1) and Dr. Müller. The German Centre for 
Cardiovascular Research (DZHK) supported Dr. Müller. Dr. Bernhagen acknowledges 
support by DFG grant SFB1123/A03 and RWTH Aachen-IZKF grant K7-1 
 
DISCLOSURES 
NONE 
 
REFERENCES 
1. Hypertension in pregnancy. Report of the american college of obstetricians and 
gynecologists' task force on hypertension in pregnancy. Obstetrics and gynecology. 
2013;122:1122-1131 
2. Fayyad AM, Harrington KF. Prediction and prevention of preeclampsia and iugr. Early human 
development. 2005;81:865-876 
3. Sacks GP, Studena K, Sargent K, Redman CW. Normal pregnancy and preeclampsia both 
produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis. Am J 
Obstet Gynecol. 1998;179:80-86 
4. Rusterholz C, Hahn S, Holzgreve W. Role of placentally produced inflammatory and 
regulatory cytokines in pregnancy and the etiology of preeclampsia. Semin Immunopathol. 
2007;29:151-162 
5. Szarka A, Rigo J, Jr., Lazar L, Beko G, Molvarec A. Circulating cytokines, chemokines and 
adhesion molecules in normal pregnancy and preeclampsia determined by multiplex 
suspension array. BMC immunology. 2010;11:59 
6. Huang SJ, Schatz F, Masch R, Rahman M, Buchwalder L, Niven-Fairchild T, Tang C, Abrahams 
VM, Krikun G, Lockwood CJ. Regulation of chemokine production in response to pro-
inflammatory cytokines in first trimester decidual cells. Journal of reproductive immunology. 
2006;72:60-73 
7. Mellembakken JR, Solum NO, Ueland T, Videm V, Aukrust P. Increased concentrations of 
soluble cd40 ligand, rantes and gro-alpha in preeclampsia--possible role of platelet 
activation. Thrombosis and haemostasis. 2001;86:1272-1276 
12 
 
8. Kaufmann P, Black S, Huppertz B. Endovascular trophoblast invasion: Implications for the 
pathogenesis of intrauterine growth retardation and preeclampsia. Biology of reproduction. 
2003;69:1-7 
9. Hunt JS. Macrophages in human uteroplacental tissues: A review. Am J Reprod Immunol. 
1989;21:119-122 
10. Yui J, Hemmings D, Garcia-Lloret M, Guilbert LJ. Expression of the human p55 and p75 tumor 
necrosis factor receptors in primary villous trophoblasts and their role in cytotoxic signal 
transduction. Biology of reproduction. 1996;55:400-409 
11. Benyo DF, Miles TM, Conrad KP. Hypoxia stimulates cytokine production by villous explants 
from the human placenta. J Clin Endocrinol Metab. 1997;82:1582-1588 
12. Yui J, Garcia-Lloret M, Wegmann TG, Guilbert LJ. Cytotoxicity of tumour necrosis factor-alpha 
and gamma-interferon against primary human placental trophoblasts. Placenta. 
1994;15:819-835 
13. Bauer S, Pollheimer J, Hartmann J, Husslein P, Aplin JD, Knofler M. Tumor necrosis factor-
alpha inhibits trophoblast migration through elevation of plasminogen activator inhibitor-1 in 
first-trimester villous explant cultures. The Journal of clinical endocrinology and metabolism. 
2004;89:812-822 
14. Xu B, Nakhla S, Makris A, Hennessy A. Tnf-alpha inhibits trophoblast integration into 
endothelial cellular networks. Placenta.32:241-246 
15. Huppertz B. The anatomy of the normal placenta. Journal of clinical pathology. 
2008;61:1296-1302 
16. Tang Z, Abrahams VM, Mor G, Guller S. Placental hofbauer cells and complications of 
pregnancy. Annals of the New York Academy of Sciences. 2011;1221:103-108 
17. Tripathi R, Rath G, Jain A, Salhan S. Soluble and membranous vascular endothelial growth 
factor receptor-1 in pregnancies complicated by pre-eclampsia. Annals of anatomy = 
Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft. 2008;190:477-489 
18. Long EO, Strubin M, Wake CT, Gross N, Carrel S, Goodfellow P, Accolla RS, Mach B. Isolation 
of cdna clones for the p33 invariant chain associated with hla-dr antigens. Proceedings of the 
National Academy of Sciences of the United States of America. 1983;80:5714-5718 
19. Veillat V, Carli C, Metz CN, Al-Abed Y, Naccache PH, Akoum A. Macrophage migration 
inhibitory factor elicits an angiogenic phenotype in human ectopic endometrial cells and 
triggers the production of major angiogenic factors via cd44, cd74, and mapk signaling 
pathways. The Journal of clinical endocrinology and metabolism. 2010;95:E403-412 
20. Noels H, Bernhagen J, Weber C. Macrophage migration inhibitory factor: A noncanonical 
chemokine important in atherosclerosis. Trends in cardiovascular medicine. 2009;19:76-86 
21. Arcuri F, Cintorino M, Vatti R, Carducci A, Liberatori S, Paulesu L. Expression of macrophage 
migration inhibitory factor transcript and protein by first-trimester human trophoblasts. 
Biology of reproduction. 1999;60:1299-1303 
22. Castro AS, Alves CM, Angeloni MB, Gomes AO, Barbosa BF, Franco PS, Silva DA, Martins-Filho 
OA, Mineo JR, Mineo TW, Ferro EA. Trophoblast cells are able to regulate monocyte activity 
to control toxoplasma gondii infection. Placenta. 2013 
23. Ferro EA, Mineo JR, Ietta F, Bechi N, Romagnoli R, Silva DA, Sorda G, Bevilacqua E, Paulesu LR. 
Macrophage migration inhibitory factor is up-regulated in human first-trimester placenta 
stimulated by soluble antigen of toxoplasma gondii, resulting in increased monocyte 
adhesion on villous explants. The American journal of pathology. 2008;172:50-58 
24. Assis DN, Leng L, Du X, Zhang CK, Grieb G, Merk M, Garcia AB, McCrann C, Chapiro J, 
Meinhardt A, Mizue Y, Nikolic-Paterson DJ, Bernhagen J, Kaplan MM, Zhao H, Boyer JL, 
Bucala R. The role of macrophage migration inhibitory factor in autoimmune liver disease. 
Hepatology. 2014;59:580-591 
25. Rebmann V, Dornmair K, Grosse-Wilde H. Biochemical analysis of plasma-soluble invariant 
chains and their complex formation with soluble hla-dr. Tissue antigens. 1997;49:438-442 
13 
 
26. Steinborn A, Rebmann V, Scharf A, Sohn C, Grosse-Wilde H. Soluble hla-dr levels in the 
maternal circulation of normal and pathologic pregnancy. American journal of obstetrics and 
gynecology. 2003;188:473-479 
27. Herse F, Lamarca B, Hubel CA, Kaartokallio T, Lokki AI, Ekholm E, Laivuori H, Gauster M, 
Huppertz B, Sugulle M, Ryan MJ, Novotny S, Brewer J, Park JK, Kacik M, Hoyer J, Verlohren S, 
Wallukat G, Rothe M, Luft FC, Muller DN, Schunck WH, Staff AC, Dechend R. Cytochrome 
p450 subfamily 2j polypeptide 2 expression and circulating epoxyeicosatrienoic metabolites 
in preeclampsia. Circulation. 2012;126:2990-2999 
28. Joerink M, Rindsjo E, van Riel B, Alm J, Papadogiannakis N. Placental macrophage (hofbauer 
cell) polarization is independent of maternal allergen-sensitization and presence of 
chorioamnionitis. Placenta. 2011;32:380-385 
29. Peyman JA, Hammond GL. Localization of ifn-gamma receptor in first trimester placenta to 
trophoblasts but lack of stimulation of hla-dra, -drb, or invariant chain mrna expression by 
ifn-gamma. J Immunol. 1992;149:2675-2680 
30. de Oliveira Gomes A, de Oliveira Silva DA, Silva NM, de Freitas Barbosa B, Franco PS, Angeloni 
MB, Fermino ML, Roque-Barreira MC, Bechi N, Paulesu LR, Dos Santos MC, Mineo JR, Ferro 
EA. Effect of macrophage migration inhibitory factor (mif) in human placental explants 
infected with toxoplasma gondii depends on gestational age. The American journal of 
pathology. 2011;178:2792-2801 
31. Cardaropoli S, Paulesu L, Romagnoli R, Ietta F, Marzioni D, Castellucci M, Rolfo A, Vasario E, 
Piccoli E, Todros T. Macrophage migration inhibitory factor in fetoplacental tissues from 
preeclamptic pregnancies with or without fetal growth restriction. Clinical & developmental 
immunology. 2012;2012:639342 
32. Brewster JA, Orsi NM, Gopichandran N, Ekbote UV, Cadogan E, Walker JJ. Host inflammatory 
response profiling in preeclampsia using an in vitro whole blood stimulation model. 
Hypertension in pregnancy. 2008;27:1-16 
33. Lockwood CJ, Matta P, Krikun G, Koopman LA, Masch R, Toti P, Arcuri F, Huang ST, Funai EF, 
Schatz F. Regulation of monocyte chemoattractant protein-1 expression by tumor necrosis 
factor-alpha and interleukin-1beta in first trimester human decidual cells: Implications for 
preeclampsia. The American journal of pathology. 2006;168:445-452 
34. Kumar A, Begum N, Prasad S, Agarwal S, Sharma S. Il-10, tnf-alpha & ifn-gamma: Potential 
early biomarkers for preeclampsia. Cellular immunology. 2013;283:70-74 
35. Fest S, Aldo PB, Abrahams VM, Visintin I, Alvero A, Chen R, Chavez SL, Romero R, Mor G. 
Trophoblast-macrophage interactions: A regulatory network for the protection of pregnancy. 
Am J Reprod Immunol. 2007;57:55-66 
36. Cemgil Arikan D, Aral M, Coskun A, Ozer A. Plasma il-4, il-8, il-12, interferon-gamma and crp 
levels in pregnant women with preeclampsia, and their relation with severity of disease and 
fetal birth weight. The journal of maternal-fetal & neonatal medicine : the official journal of 
the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal 
Societies, the International Society of Perinatal Obstet. 2012;25:1569-1573 
37. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, 
Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like 
tyrosine kinase 1 (sflt1) may contribute to endothelial dysfunction, hypertension, and 
proteinuria in preeclampsia. The Journal of clinical investigation. 2003;111:649-658 
38. Faas MM, Spaans F, De Vos P. Monocytes and macrophages in pregnancy and pre-eclampsia. 
Frontiers in immunology. 2014;5:298 
39. Seval Y, Korgun ET, Demir R. Hofbauer cells in early human placenta: Possible implications in 
vasculogenesis and angiogenesis. Placenta. 2007;28:841-845 
40. Redman CW, Sargent IL. Immunology of pre-eclampsia. Am J Reprod Immunol. 2010;63:534-
543 
14 
 
41. Sanchez-Nino MD, Sanz AB, Ruiz-Andres O, Poveda J, Izquierdo MC, Selgas R, Egido J, Ortiz A. 
Mif, cd74 and other partners in kidney disease: Tales of a promiscuous couple. Cytokine & 
growth factor reviews. 2013;24:23-40 
42. Morgan LZ, Rollins B, Sequeira A, Byerley W, DeLisi LE, Schatzberg AF, Barchas JD, Myers RM, 
Watson SJ, Akil H, Bunney WE, Jr., Vawter MP. Quantitative trait locus and brain expression 
of hla-dpa1 offers evidence of shared immune alterations in psychiatric disorders. 
Microarrays (Basel). 2016;5 
43. Ghiglione Y, Rodriguez AM, De Candia C, Carobene M, Benaroch P, Schindler M, Salomon H, 
Turk G. Hiv-mediated up-regulation of invariant chain (cd74) correlates with generalized 
immune activation in hiv+ subjects. Virus research. 2012;163:380-384 
44. Zenclussen ML, Linzke N, Schumacher A, Fest S, Meyer N, Casalis PA, Zenclussen AC. Heme 
oxygenase-1 is critically involved in placentation, spiral artery remodeling, and blood 
pressure regulation during murine pregnancy. Frontiers in pharmacology. 2014;5:291 
45. Rice GE, Scholz-Romero K, Sweeney E, Peiris H, Kobayashi M, Duncombe G, Mitchell MD, 
Salomon C. The effect of glucose on the release and bioactivity of exosomes from first 
trimester trophoblast cells. The Journal of clinical endocrinology and metabolism. 
2015;100:E1280-1288 
46. Harmon QE, Engel SM, Wu MC, Moran TM, Luo J, Stuebe AM, Avery CL, Olshan AF. 
Polymorphisms in inflammatory genes are associated with term small for gestational age and 
preeclampsia. Am J Reprod Immunol. 2014;71:472-484 
47. Bikoff EK, Huang LY, Episkopou V, van Meerwijk J, Germain RN, Robertson EJ. Defective major 
histocompatibility complex class ii assembly, transport, peptide acquisition, and cd4+ t cell 
selection in mice lacking invariant chain expression. The Journal of experimental medicine. 
1993;177:1699-1712 
48. Shachar I, Flavell RA. Requirement for invariant chain in b cell maturation and function. 
Science. 1996;274:106-108 
49. Sauler M, Leng L, Trentalange M, Haslip M, Shan P, Piecychna M, Zhang Y, Andrews N, 
Mannam P, Allore H, Fried T, Bucala R, Lee PJ. Macrophage migration inhibitory factor 
deficiency in chronic obstructive pulmonary disease. American journal of physiology. Lung 
cellular and molecular physiology. 2014;306:L487-496 
50. Mun SH, Won HY, Hernandez P, Aguila HL, Lee SK. Deletion of cd74, a putative mif receptor, 
in mice enhances osteoclastogenesis and decreases bone mass. Journal of bone and mineral 
research : the official journal of the American Society for Bone and Mineral Research. 
2013;28:948-959 
51. Rossant J, Cross JC. Placental development: Lessons from mouse mutants. Nature reviews. 
Genetics. 2001;2:538-548 
52. Watson ED, Cross JC. Development of structures and transport functions in the mouse 
placenta. Physiology (Bethesda). 2005;20:180-193 
53. Simmons DG, Rawn S, Davies A, Hughes M, Cross JC. Spatial and temporal expression of the 
23 murine prolactin/placental lactogen-related genes is not associated with their position in 
the locus. BMC genomics. 2008;9:352 
54. Croy BA. Reproductive immunology issue one: Cellular and molecular biology. Cellular & 
molecular immunology. 2014;11:405-406 
55. Coan PM, Angiolini E, Sandovici I, Burton GJ, Constancia M, Fowden AL. Adaptations in 
placental nutrient transfer capacity to meet fetal growth demands depend on placental size 
in mice. The Journal of physiology. 2008;586:4567-4576 
56. Rasmussen LG, Lykke JA, Staff AC. Angiogenic biomarkers in pregnancy: Defining maternal 
and fetal health. Acta obstetricia et gynecologica Scandinavica. 2015;94:820-832 
57. Arck PC, Hecher K. Fetomaternal immune cross-talk and its consequences for maternal and 
offspring's health. Nature medicine. 2013;19:548-556 
  
15 
 
FIGURES 
 
Figure 1. CD74 is downregulated in preeclamptic placenta. A) CD74 expression is 
downregulated in placentas of preeclamptic women (PE) compared to healthy women 
(control; n=28). PE is subdivided in early onset PE (delivery <34 week of gestation; grey bar; 
n=26) and late onset PE (delivery ≥34 week of gestation; black bar; n=24) (**p<0.01; 
***p<0.001; Bonferroni's multiple comparisons test). B) CD74 protein (33 and 35 kDa) is 
lowered in placenta lysates of early and late onset PE (n=2 each). C) Confirmation by flow 
cytometry; representative CD74-positive gating is shown for whole placenta cell population 
(left panel). Mean fluorescent intensity (MFI) of CD74 is lowered in general placenta cell 
population of late PE vs. control (right panel) (n=10 (PE) and 6 (control); ***p=0.001; Mann 
Whitney test).  
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Figure 2. CD74 is highly expressed in placental macrophages (Hofbauer cells) and 
downregulated in preeclamptic Hofbauer cells. A) By flow cytometry; representative CK7-
positive gating (trophoblast marker) and CD14-positve gating (macrophage marker) is shown 
for whole placenta cell population (left panel) of healthy controls. Solely 2.6±0.8 % of 
trophoblasts (CK7-positive) vs. 93.1±1.1 % of Hofbauer cells (CD14-positive) were positive 
for CD74 staining (right panel) (n=6; p<0.01; Mann Whitney test). B) Immunostaining showed 
that CD74 (red) is co-localized with CD163 (green) (Hofbauer cells; open arrows; upper 
panel) but not with CK7 (green). C) Flow cytometry on whole placenta cell population 
revealed that CD74 was less present in CD14-positive cells of placentas from late 
preeclamptic women (PE) compared to healthy women (control) (left panel). The mean 
fluorescent intensity (MFI) of CD74-CD14-positive cells was lower in PE vs. control (middle 
panel). Percentage of CD14-positive cells in all placental cells was not changed in PE (n=10) 
vs. control (n=6) (right panel) (*p<0.05, **p<0.01; Mann Whitney test). 
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Figure 3. Illustration of the maternal-fetal-interface. Tissue and cells from fetal origin are 
illustrated in blue. Maternal tissue and cells are illustrated in red. Fetal cytotrophoblasts 
invade into the maternal tissue and remodel the maternal spiral artery. Fetal macrophages 
(Hofbauer cells) interact with the fetal villous cytotrophoblast via adhesion molecules and 
cytokines.  
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Figure 4. Dysregulated expression and function of CD74 silenced M(-) and M(IL-4) 
macrophages. A) Heatmap represents microarray analysis for indicated conditions (left 
panel). Genes were pre-selected by 5% FDR (Subdued parametric three way ANOVA, 
Benjamini Hochberg FDR corrected) for CD74 silenced (siCD74) vs. non-targeting control 
(NT). Genes undergoing 65% FDR were plotted for siCD74 vs NT in M(IL-4) macrophages 
(right panel). Genes in orange correlate to “placenta” (by literature), genes in red encode 
adhesion molecules and CD74 is indicated in green (both panels). B) Adhesion of CD74 
silenced macrophages (M(IL-4) siCD74) to first trimester trophoblast derived cell line 
(SGHPL-4) was lowered compared to control macrophages (M(IL-4) NT) as shown in 
representative pictures (left panel) and in summary of 3 independent experiments (right 
panel) (**p<0.01; unpaired t test). 
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Figure 5. Cytokine/chemokine-upregulation of macrophages derived from CD74 
knockout mice (CD74-/-) and expression profile in a trophoblast cell line. A) In vitro 
activated bone marrow derived (BMD) macrophages (M(IL-4+IL-13)) from CD74-/- mice 
produced more tumor necrosis factor α (TNFα) and chemokine (C-C motif) ligand 5 (CCL5) 
compared to BMD M(IL-4+IL-13) from wild type (WT) mice (left panel) (n=6 each; *p<0.05, 
unpaired t test). Co-culture with human first trimester trophoblast derived cell line (SGHPL-4) 
enhanced the effect (right panel) (n=6 each, ***p<0.001, ****p<0.0001; unpaired t test). 
Secretion of monocyte chemoattractant protein-1 (MCP-1) was solely enhanced under co-
culture conditions (n=4 each, *p<0.05, Mann Whitney test). All factors were secreted by 
macrophages, as Luminex assay was specific for mice. B) Co-culturing of BMD M(IL-4+IL-
13) from CD74-/- with SGHPL-4 lowered cell amount of SGHPL-4 when compared to BMD 
M(IL-4+IL-13) from WT (n=30 each; **p<0.01, unpaired t test). C) SGHPL-4 stimulated by the 
combination of MCP-1, CCL5 and TNFα for 6h and 24h express more Cytochrome P450 
Subfamily 2J Polypeptide 2 (CYP2J2), soluble Fms-like tyrosine kinase 1 (sFlt1), TNFα and 
Interleukin 8 (IL-8). The ratio of the expression of sFlt1 and the placental growth factor 
(PLGF), the sFlt1/PLGF ratio was also enhanced (n=9, *p<0.05, **p<0.01, ***p<0.001; 
ANOVA followed by Dunnett post hoc testing). 
20 
 
 
Figure 6. Pro-inflammatory signature of macrophages derived from CD74 knockout 
mice (CD74-/-). In vitro differentiated bone marrow derived (BMD) macrophages (M(-)) from 
CD74-/- mice express more tumor necrosis factor α (Tnfα), interleukin 6 (Il-6), chemokine (C-
C motif) ligand 5 (Ccl5), nitric oxide synthase 2 (Nos2) and monocyte chemoattractant 
protein-1 (Mcp-1) compared to BMD M(-) from wild type (WT) mice. Tnfα and Il-6 were also 
higher expressed in BMD M(IL-4+IL-13) from CD74-/- mice compared to WT. Marker for LPS 
signature (Nos2, Ccl5, IL-6, Tnfα, Mcp-1) and IL-4+IL-13 signature (arginase 1 (Arg1), 
Resistin-like molecule alpha1 (Fizz1), mannose receptor 1 (Mrc-1), programmed death ligand 
2 (Pd-l2)) were fully activated in M(LPS) and M(IL-4+IL-13) respectively and pro-
inflammatory activation by LPS was further increased by CD74-/- in regard of Tnfα, Il-6, Nos2 
and Mcp-1 (n=6 each;*p<0.05, **p<0.01, ***p<0.001; unpaired t test). 
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Figure 7. Fetal growth restriction and disturbed placenta morphology in CD74 
knockout mice (CD74-/-). A) Pup and placental weights were lower in CD74-/- (n=32) vs. WT 
(n=33). Litter size was also decreased in CD74-/- (n=17) vs. WT (n=28) (*p<0.05, **p<0.01 
and ****p<0.0001; Mann Whitney test). B) Representative pictures of Masson stained mid-
sagittal placental tissue sections used to carry out the histomorphological analysis (upper 
panel). Zones are marked and indicated by L (labyrinth zone) and Jz (junctional zone). The 
overall size of the placenta was decreased in CD74-/- tissues (lower panel) whereas the ratio 
between the labyrinth/junctional zones was enhanced in CD74-/- (n=13) in comparison to WT 
(n=17). The area of the junctional zone of CD74-/- placentas was smaller compared to those 
of WT. (**p<0.01, ***p<0.001; unpaired t test). 
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Figure 8. Impaired spiral artery remodeling in CD74 knockout mice (CD74-/-). A) α-actin 
staining is shown in representative pictures of arteries. Arrows are indicating α-actin stained 
VSMC’s. B) Spiral arteries of CD74-/- showed more α-actin in the vessel wall when compared 
to wild type (WT), indicating an impaired remodeling. Bar graphs show % of remodeling of 
artery (total loss of α-actin = 100%). (M): n=85 (WT), n=95 (CD74-/-); (D): n=36 (WT), n=24 
(CD74-/-); *p<0,05, **p<0,01; unpaired t test. 
 
